MedTrace Logo

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

NCT02262546 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-10-13

No results posted yet for this study

Summary

The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo

Conditions

  • Healthy

Interventions

DRUG

Pramipexole extended-release (ER) tablets

DRUG

Pramipexole immediate-release (IR) tablets

DRUG

Moxifloxacin

DRUG

Pramipexole Placebo

DRUG

Moxifloxacin Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262546 on ClinicalTrials.gov